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AbstrAct
Introduction: Recently, incretin-related 
therapy has been developed for the new 
treatment of diabetes mellitus; however, 
incretin response to glucose ingestion in 
normal glucose tolerant (NGT) subjects 
has not been clarified in detail with special 
reference to the role of incretin hormones, 
glucagon, and a family history of diabetes. 
Methods: We conducted a 75 g oral glucose 
tolerance test in 30 NGT subjects. Results: The 
total glucose-dependent insulinotropic peptide 
(GIP)-AUC0-120 (area under the curve over 
a period of 0-120 minutes) was correlated 
with immunoreactive insulin (IRI)-AUC0-120
(P<0.05), insulinogenic index (II; P<0.05), ΔIRI 
between 0 and 120 minutes (P<0.05). Active 
glucagon-like peptide-1 (GLP-1) AUC0-120
was correlated inversely both with Δ glucose 
between 0 and 30 minutes (P<0.01) and with 
Δ immunoreactive glucagon between 0 and 
30 minutes (P<0.05). Δ Total GIP between 0 
and 15 minutes (P<0.01), Δ total GIP between 
0 and 30 minutes (P<0.05), and the total GIP-
AUC0-120 (P<0.05) in the subjects with a family 
history of type 2 diabetes were significantly 
higher than those in the subjects without 
a family history. Conclusion: These results 
suggest that GIP possibly facilitates insulin 
secretion in response to oral glucose load 
directly and active GLP-1 may exert the 
glucoregulatory action via the suppression of 
glucagon secretion in NGT subjects. Notably, 
the subjects with a family history of diabetes 
exert significantly higher GIP response in the 
early phase of glucose load compared with 
those without a family history.
Keywords: diabetes mellitus; glucagon; glucagon-
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IntroductIon
Glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1) 
are incretin hormones that are released from 
enteroendocrine cells within minutes after food 
intake. GIP is secreted from enteroendocrine 
cells (K cells) primarily in the proximal small 
intestine (duodenum and jejunum), while 
GLP-1 is secreted from enteroendocrine cells 
(L cells) that are scattered throughout the small 
bowel (primarily in the distal portion) and 
colon.1 Both GIP and GLP-1 have been shown 
to stimulate insulin secretion in response to 
glucose and nutrient ingestion.2 The primary 
role of GIP is supposed to stimulate the 
secretion of insulin from pancreatic β cells, 
especially in the postprandial state. In addition 
to its insulinotropic effect, GLP-1 has a 
potent glucagonostatic action, inhibits gastric 
emptying, decreases food intake, and slows 
the rate of endogenous glucose production, all 
of which would ameliorate the blood glucose 
levels in type 2 diabetes mellitus (T2DM). GLP-1 
shows direct effects through GLP-1 receptors 
in the hypothalamus, thereby regulating the 
appetite, food intake, and body weight in the 
“gut-brain axis” (the reciprocal system between 
the gastrointestinal tract and central nervous 
system to regulate short- and long-term 
energy homeostasis).1
The earlier studies on the response of both 
incretin hormones to an oral glucose tolerance 
test (OGTT) and test meal revealed that the 
incretin effect of Caucasian patients with T2DM 
is significantly lower than healthy subjects.3,4
Conversely, in the three studies demonstrating 
incretin responses after ingestion of glucose and/
or nutrients in Japanese subjects,5-7 any difference 
between T2DM patients with or without obesity 
and nondiabetic control subjects could not be 
found out.
Whether the abnormality of the incretin 
response to the nutrient might be involved 
in the pathophysiological mechanisms of 
the development of T2DM or not awaits 
further investigation.
At the first step of the analysis of the 
mechanism, it is necessary to reveal the 
response of incretin to glucose or food intake 
in normal glucose-tolerant (NGT) subjects in 
detail with special reference to the relationship 
between incretin hormone responses and 
insulin, glucagon secretion, gender, metabolic 
parameters inclusive of body mass index (BMI), 
waist circumference, and a family history of 
diabetes in particular.
In this study, the various parameters were 
investigated after an intake of 75 g glucose in 
order to clarify the relationship between the 
responses of incretin hormones and glucose, 
insulin, or glucagon in 30 healthy subjects who 
are currently NGT.
MAterIAls And Methods
Materials
Thirty healthy subjects, who were a group of 
medical students within a pregraduate course, 
participated in this study. All of them had NGT. 
The exclusion criteria were subjects who had 
any major illness or premenopausal women who 
were pregnant or nursing. This study has been 
approved by the Ethics Committee of Hyogo 
College of Medicine. All participants provided 
written informed consent before the start of 
the study.
Methods
To identify the baseline characteristics of incretin 
secretion in Japanese subjects, the influence of 
body weight, BMI, height, gender, and a family 22 Diabetes Ther (2011)  2(1):20-28.
history of diabetes on the hormonal response to 
oral glucose ingestion were also examined.
The OGTT consisted of ingesting 75 g 
glucose (Toleran G®, Ajinomoto Pharma, Tokyo, 
Japan) in the overnight fasting state within 
5 minutes. For active GLP-1 and total GIP 
analysis, catheters were placed in cubital veins 
and blood samples were withdrawn directly into 
the blood collection ethylenediaminetetraacetic 
acid-disodium salt coated tubes (1.25 mg/mL 
blood) containing aprotinin and an inhibitor 
of dipeptidyl peptidase-4 (10 μL/mL blood; 
Linco Research Inc., MO, USA) before the start 
of the OGTT and 15, 30, 60, and 120 minutes 
after ingestion, respectively. The levels of 
plasma glucose, immunoreactive insulin (IRI), 
immunoreactive glucagon (IRG), total GIP, and 
active GLP-1 were measured at each time interval. 
Plasma glucose concentrations were measured 
immediately by the glucose oxidase method. IRI 
was measured using chemiluminescent enzyme 
immunoassay (Fujirebio Inc., Tokyo, Japan). 
Plasma levels of glucagon were measured using 
a radioimmunoassay via the glucagon kit 
daiichi-II (TFB Corp., CA, USA). Plasma levels of 
active GLP-1 were measured using an enzyme-
linked immunosorbent assay (ELISA), using 
the GLP-1 active ELISA kit (Millipore Corp., 
MA, USA) according to the manufacturer’s 
instructions. Plasma levels of the total GIP 
were also measured using an ELISA, using the 
human GIP (total) ELISA kit (Millipore Corp., 
MA, USA).
Statistical Analysis
The results of statistical analysis were shown as the 
mean ± standard deviation (SD) unless otherwise 
specified. The trapezoidal method was used to 
calculate all areas under the curves (AUCs). The 
homeostasis model assessment was used both 
for assessing insulin resistance (HOMA-R) and 
insulin secretion (HOMA-β).8 HOMA-R was 
calculated as fasting plasma glucose (mg/dL) × 
fasting serum insulin (μIU/mL)/405. HOMA-β
was calculated as (360× fasting serum insulin 
[μIU/mL]) / (fasting plasma glucose [mg/dL] 
–63). The insulinogenic index (II) was calculated 
as the ratio of the increment of serum insulin 
to plasma glucose concentration 30 minutes 
after an oral glucose load (IRI Δ0-30  minutes/
glucose Δ0-30 minutes).9 Single Pearson correlation 
analysis was used to examine bivariate 
relationships. The unpaired t-test was used 
when two separate sets of samples (family 
history [+]/[–]) were obtained. A P value of less 
than 0.05 was taken to indicate statistically 
significant difference.
results
As shown in Table 1, the age of subjects was 
24.7±2.3 years and BMI was 21.8±3.5 kg/m2. 
The average BMI of women (10 subjects) was 
19.3 kg/m2 and men (20 subjects) was 23.1 kg/m2. 
The mean plasma glucose, IRI, total GIP, active 
GLP-1, and IRG levels in the subjects are 
summarized in Figure 1. The mean plasma glucose 
and IRI peaked at 30 minutes (Figure 1A).
The mean active GLP-1 peaked at 15 minutes 
and the peak level of active GLP-1 was 
10.6 pmol/L. The level of total GIP increased 
steeply in 15 minutes, and thereafter increased 
gradually with time, whereas the IRG gradually 
decreased during the observation period. 
The peak level of total GIP was 265.5 pg/mL 
(Figure 1B).
The total GIP-AUC0-120 was related to the 
IRI-AUC0-120 (R=0.39,  P<0.05), II (R=0.40, 
P<0.05), and Δ IRI between 0 and 120 minutes 
(R=0.40, P<0.05), as shown in Figure 2A, B, 
and C, respectively. Conversely, the active 
GLP-1-AUC0-120 was inversely correlated with 
Δ glucose between 0 and 30 minutes (R=–0.47, Diabetes Ther (2011)  2(1):20-28. 23
P<0.01) and Δ IRG between 0 and 30 minutes 
(R=–0.40, P<0.05), as shown in Figure 3A and 
B, respectively.
Body weight was correlated with HOMA-R 
(R=0.50,  P<0.01), II (R=0.40,  P<0.05), and 
HOMA-β (R=0.37, P<0.05). BMI was correlated 
with HOMA-R (R=0.50, P<0.01) and HOMA-β
(R=0.37, P<0.05), and waist circumference was 
correlated with HOMA-R (R=0.44, P<0.05) and 
HOMA-β (R=0.39,  P<0.05). However, body 
weight, BMI, waist circumference, height, and 
gender were not related to the secretory response 
of total GIP (Δ GIP between 0 minutes and 15, 
30, 60, 120 minutes, and GIP-AUC0-120), active 
GLP-1 (Δ active GLP-1 between 0 minutes and 15, 
30, 60, 120 minutes, and active GLP-1-AUC0-120), 
and IRG (Δ IRG between 0 minutes and 15, 30, 
60, 120 minutes, and IRG-AUC0-120).
The presence or absence of T2DM family 
history was not correlated with BMI, waist 
circumference, HOMA-R, II, HOMA-β, and 
IRI-AUC0-120 as shown in Table 2. It was not 
correlated with the secretory response of active 
GLP-1 (Δ active GLP-1 between 0 minutes and 
15, 30, 60, 120 minutes, and active GLP-1-
AUC0-120) and IRG (Δ IRG between 0 minutes 
and 15, 30, 60, 120 minutes, and IRG-
Table 1. Clinical characteristics of 30 Japanese subjects 
with normal glucose tolerance.
Week 0
Age, years 24.7±2.3
Gender, n
  Men 20
  Women 10
Height, m 1.67±0.08
Body weight, kg 60.8±11.6
BMI, kg/m2 21.8±3.5
Waist circumference, cm 76.2±11.6
HOMA-R 1.1±0.8
HOMA-β, % 68.3±45.6
Insulinogenic index  0.8±0.5
Family history of diabetes*  [+]13/[–] 17
(presence [+]/absence [–]), n
Of the 13 subjects with the presence of a 
family history:
  Subjects with first-degree relative, n 4
  Subjects with second-degree relative, n 8
  Subjects with third-degree relative, n 1
*Defined as subjects with a first- to third-degree relative 
with T2DM.
BMI=body mass index; HOMA-R=homeostasis model 
assessment for insulin resistance; HOMA-β=homeostasis 
model assessment for insulin secretion; T2DM=type 2 
diabetes mellitus.
Figure 1. Results of oral glucose tolerance test in (A) 
plasma glucose and insulin (B) glucagon, total glucose-
dependent insulinotropic peptide, and active glucagon-like 
peptide-1. Data are calculated as mean±SD. GIP=glucose-
dependent insulinotropic peptide; GLP-1=glucagon-
like peptide-1; IRG=immunoreactive glucagon; 
IRI=immunoreactive insulin. 
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AUC0-120), respectively. However, Δ total GIP 
between 0 and 15 minutes (R=0.54, P<0.01), 
Δ  total GIP between 0 and 30  minutes 
(R=0.39, P<0.05), and the total GIP-AUC0-120 
(R=0.39, P<0.05) in subjects with a family 
history of diabetes were significantly higher 
than those subjects without a family history 
of diabetes. In order to confirm this, unpaired 
t-tests were used to examine whether there 
was a difference between the Δ  total GIP 
between 0 and 15  minutes,  Δ  total GIP 
between 0 and 30 minutes, and GIP-AUC0-120 
in subjects with a family history of diabetes 
or no family history of diabetes. Total GIP-
AUC0-120 (P=0.039) in subjects with a family 
history of diabetes were significantly higher 
than those subjects without a family history 
of diabetes, and as shown in Figure 4, Δ total 
GIP between 0 and 15 minutes (P=0.0032) 
and Δ total GIP between 0 and 30 minutes 
(P=0.041) in subjects with a family history of 
Figure 2. (A) Correlation between total glucose-dependent 
insulinotropic polypeptide (GIP) area under the curve 
(AUC)0-120 and immunoreactive insulin (IRI)-AUC0-120 
(y=1.797x+205.79; R=0.39; P<0.05). (B) Correlation 
between total GIP-AUC0-120 and insulinogenic index 
(y=7086.1x+21,774; R=0.40; P<0.05). (C) Correlation 
between total GIP-AUC0-120 and ΔIRI between 0 and 
120 minutes (y=140.35x+24,012; R=0.40; P<0.05). 
AUC=area under the curve; GIP=glucose-dependent 
insulinotropic peptide; II=insulinogenic index; 
IRI=immunoreactive insulin.
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Figure 3. (A) Correlation between active glucagon-like 
peptide-1 (GLP-1) area under the curve (AUC)0-120 
and Δglucose between 0 and 30 minutes (y=–19.551x 
+1920.9; R=–0.47; P<0.01). (B) Correlation between 
active GLP-1-AUC0-120 and Δ immunoreactive glucagon 
(IRG) between 0 and 30 minutes (y=–16.545x+720.37; 
R=–0.40; P<0.05). AUC=area under the curve; 
GIP=glucose-dependent insulinotropic peptide; 
IRG=immunoreactive glucagon.
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diabetes were significantly higher than those 
subjects without a family history of diabetes.
dIscussIon
The analytical data of incretin responses and 
kinetics of healthy Japanese subjects are scant;5-7 
therefore, in the present study 30 Japanese NGT 
subjects were recruited.
Nauck et al.10 administered synthetic human 
GIP, GLP-1, and placebo under hyperglycemic 
clamp conditions in nine T2DM and nine age- 
and weight-matched NGT subjects. Both GIP and 
GLP-1 (7-36 amide) dose-dependently augmented 
insulin secretion in both the T2DM and NGT 
group.10 Cataland et al.11 gave 75 g glucose to 
21 healthy volunteers, and their serum GIP 
levels increased after oral glucose ingestion.
The present study shows that the total GIP-
AUC0-120 in healthy Japanese subjects positively 
correlated with the IRI-AUC0-120 (P<0.05), II 
(P<0.05), and Δ IRI between 0 and 120 minutes 
(P<0.05). The present study has demonstrated 
that GIP clearly augmented insulin secretion 
in response to an oral glucose load in healthy 
subjects, which suggests that the secretory 
response of total GIP, which is secreted from 
K cells primarily in the proximal intestine 
after glucose ingestion, could be a potent 
trigger and/or stimulant of insulin secretion in 
healthy subjects.
Conversely, active GLP-1-AUC0-120 was not 
related to IRI-AUC0-120 and II. Active GLP-1 
did not show any significant augmentation 
of insulin secretion in Japanese NGT subjects. 
Table 2. Clinical characteristics of the enrolled subjects with or without a family history of diabetes.
Family history of diabetes* 
Presence (+) Absence (–) P value
Number of subjects 13 17
Age, years 24.8±2.7 24.5±1.9 NS
BMI, kg/m2 21.2±3.4 22.3±3.6 NS
Waist circumference, cm 73.8±12.6 78.1±10.8 NS
HOMA-R 1.1±0.9 1.2±0.6 NS
HOMA-β, % 64.3±49.8 71.4±43.4 NS
Insulinogenic index 0.8±0.5 0.8±0.5 NS
IRI-AUC0-120, μU h/mL 3840.2±1493.0 4398.4±2321.5 NS
*Defined as subjects with first- to third-degree relatives with T2DM.
AUC=area under the curve; BMI=body mass index; HOMA-R=homeostasis model assessment for insulin resistance; 
HOMA-β=homeostasis model assessment for insulin secretion; IRI=immunoreactive insulin; NS=nonsignificant; 
T2DM=type 2 diabetes mellitus.
Figure 4. Correlation of Δglucose-dependent 
insulinotropic polypeptide (GIP) and a family history 
of type 2 diabetes mellitus (T2DM), defined as having 
a first- to third-degree relative with T2DM. **P<0.01. 
*P<0.05. DM=diabetes mellitus; GIP=glucose-dependent 
insulinotropic peptide; NS=nonsignificant.
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However, active GLP-1-AUC0-120 was correlated 
inversely both with Δ glucose between 0 and 
30 minutes (P<0.01) and with Δ IRG between 0 
and 30 minutes (P<0.05). This means that GLP-1 
may exert its glucoregulatory action via the 
suppression of glucagon secretion rather than 
the stimulation of insulin secretion in healthy 
Japanese subjects. This effect of GLP-1 possibly 
contributes to lower the plasma glucose level as 
a result of reduction in hepatic glucose output.1
The secretory response of GLP-1 has been 
reported to be decreased in T2DM,3,4,12 which 
could weaken the incretin effect of GLP-1 on the 
reduction in hepatic glucose output.
In addition, GLP-1 may also lower plasma 
glucose levels by retarding gastric emptying, 
because there is an inverse relationship between 
gastric emptying of glucose and plasma GLP-1.13
To establish the precise mechanism of the 
inverse relationship between GLP-1 secretion 
and plasma glucose, the function of gastric 
emptying of glucose needs to be examined.
The key factors regulating the GIP/GLP-1 
response after glucose ingestion by NGT and 
abnormal glucose tolerant subjects are not 
well understood. Vollmer et al.14 reported 
that female gender was positively related to 
GLP-1 concentration. Carroll conducted a study 
to determine the influence of BMI and gender 
on postprandial hormone responses such as 
insulin, leptin, ghrelin, active GLP-1, and 
glucagon. He found that men had significantly 
greater fasting (P=0.02) and postprandial 
(P=0.03) glucagon, and men tended to have 
higher GLP-1 concentrations (P=0.06). Obese 
subjects had higher fasting glucose and insulin 
concentrations, while BMI did not affect 
the postprandial GLP-1 response.15 Several 
studies have demonstrated that gender did not 
influence glucagon responses to stimuli such as 
exercise and hypoglycemia.16-18 Therefore, in the 
present study, the influence of gender, height, 
body weight, BMI or waist circumference on 
the incretin hormones and glucagon in healthy 
Japanese subjects was examined. However, no 
significant relationship among these factors in 
Japanese NGT subjects was found. Neither gender 
nor physical constitution affected the secretion 
of incretin hormones in the Japanese subjects.
In addition, we examined whether a family 
history of diabetes (presence or absence of T2DM 
patients within the third degree of kinship) was 
correlated with the level and/or the response of 
incretin hormones, because Japanese patients 
with T2DM usually have impaired insulin 
secretion even in the early phase of diabetes 
rather than insulin resistance.19 In earlier studies 
in Western countries, the incretin effect in 
relatives of T2DM patients has been examined, 
and it is still controversial. In a German 
study, a lower insulin secretory response to 
exogenous GIP in first-degree relatives of 
patients with T2DM was shown,20 and in a 
Danish study, the daytime (after meals) AUC 
for plasma GIP was significantly increased in 
the relatives of diabetes patients compared with 
control subjects without any family history of 
diabetes.21 However, in another German study, 
the incretin effects were similar in first-degree 
relatives of patients with T2DM and healthy 
control subjects.22 As there had been no attempt 
to reveal the relationship between a family 
history of diabetes and incretin response in 
Japanese subjects, we enrolled Japanese subjects 
who were NGT with or without a family history 
of diabetes. Interestingly, we found that Δ total 
GIP between 0 and 15 minutes (R=0.54, P<0.01), 
Δ total GIP between 0 and 30 minutes (R=0.39, 
P<0.05), and the total GIP-AUC0-120 (R=0.39, 
P<0.05) in the subjects with a family history 
of diabetes were significantly higher than those 
in the subjects without a family history of 
diabetes. Conversely, IRI, HOMA-R, HOMA-β, 
II, active GLP-1, and IRG were not correlated Diabetes Ther (2011)  2(1):20-28. 27
with the presence or absence of a family history 
of diabetes.
It has been speculated that the loss of 
insulinotropic action of GIP in T2DM might occur 
as a result of either chronic desensitization of 
GIP receptors,23 or a reduction in the expression 
of GIP receptors on pancreatic β cells.24,25 Both 
abnormalities of GIP receptors might have already 
been induced in an NGT state with the presence 
of a family history, and a hypersecretion of GIP 
could potentially compensate for a reduced 
insulinotropic effectiveness of GIP, which could 
enhance insulin secretion particularly in the 
early phase in response to a glucose load.
Another hypothesis to account for the 
hypersecretion of GIP in NGT subjects with T2DM 
family history is the rapid gastric emptying. Since 
Phillips et al.26 reported that recently diagnosed 
T2DM patients emptied their stomach more 
rapidly than nondiabetic control subjects, in the 
subjects with a family history of T2DM, the GIP 
secretion from the upper small intestine may 
already be augmented by rapid gastric emptying 
even in an NGT state. Furthermore, whether the 
background mechanism of the phenomenon 
would depend on the differences in the rate 
of glucose absorption in the small intestine 
and density of K cells should be examined in 
the future.
The augmented response of GIP after glucose 
load in subjects with a family history of T2DM 
in the present study could be related, in part, 
to the onset mechanism of Japanese T2DM 
patients, although further study is required. The 
low number of subjects is acknowledged as a 
limitation of the study.
In conclusion, the present study was 
designed to investigate the secretory patterns 
of two incretin hormones to OGTT and the 
relationship between incretin hormones and 
glucose, insulin, or glucagon response in healthy 
Japanese subjects. The results demonstrate 
that, at least in subjects enrolled in the study, 
GIP from the upper small intestine may play a 
role as an insulinotropic hormone and GLP-1 
may play a role as a glucagonostatic hormone 
collaboratively. Furthermore, healthy subjects 
with a family history of diabetes who have 
normal glucose tolerance exert a significantly 
higher GIP response, especially in the early 
phase of GIP secretion in response to an oral 
glucose load compared with those without a 
family history of T2DM.
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